IMRN (IMRN) Stock Price & Analysis
IMRN (IMRN) fell 5.13% to USD 1.11 as of July 25, 2026 at 07:45 UTC, according to Nexqual real-time market data.
IMRN last closed at USD 1.17; the session ranged USD 1.08–1.17 on volume of 18,753 shares. Market capitalization is $8.96M, with a 52-week range of USD 0.68–2.39 (NCM). Source: Nexqual, July 25, 2026 at 07:45 UTC.
Key Statistics (as of July 25, 2026 at 07:45 UTC)
| Price | USD 1.11 |
|---|---|
| Change | ▼ 5.13% (down) |
| Previous Close | USD 1.17 |
| Open | USD 1.17 |
| Day Range | USD 1.08 – 1.17 |
| 52-Week Range | USD 0.68 – 2.39 |
| Volume | 18,753 shares |
| Market Cap | $8.96M |
| Exchange | NCM |
Technical Analysis (IMRN)
Nexqual's technical model rates IMRN "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 07:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.15 (neutral) |
| vs SMA50 | Below (USD 1.15) |
| MACD | 0.01 (positive) |
Analyst Ratings (IMRN)
Wall Street analysts rate IMRN "None" based on 1 analysts, with a mean price target of USD 3.9 (range USD 3.9–3.9), per Nexqual as of July 25, 2026 at 07:45 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 3.9 |
| High Target | USD 3.9 |
| Low Target | USD 3.9 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (IMRN)
Source: Nexqual, July 25, 2026 at 07:45 UTC.
Financials & Fundamentals (IMRN)
| Total Revenue | $7.48M |
|---|---|
| Revenue Growth (YoY) | +4.80% |
| Gross Margin | +63.69% |
| Operating Margin | -47.16% |
| Profit Margin | -62.14% |
| ROE | -39.68% |
| Debt / Equity | 1.56 |
| Current Ratio | 8.04 |
| Total Cash | $10.00M |
| Total Debt | $203,914 |
| Free Cash Flow | $-3.42M |
Source: Nexqual, July 25, 2026 at 07:45 UTC.
Financial Health Score (IMRN)
Nexqual rates IMRN's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:45 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $10M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Critical — ROE -40%, ROA -21.9% |
Ownership (IMRN)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +1.05% |
| Shares Outstanding | 8.07M |
| Float | 7.99M |
| Short % of Float | +1.54% |
Source: Nexqual, July 25, 2026 at 07:45 UTC.
Leadership (IMRN)
IMRN is led by Steven George Lydeamore (age 57), Chief Executive Officer, per Nexqual as of July 25, 2026 at 07:45 UTC.
| Chief Executive Officer | Steven George Lydeamore (age 57) |
|---|---|
| Chief Operating Officer | Jerry Kanellos (age 64) |
| Chief Financial Officer | Aaron Laurita |
Major Backers & Investors (IMRN)
Notable institutional backers of IMRN include Morgan Stanley, Xtx Topco Ltd, Citadel, according to Nexqual as of July 25, 2026 at 07:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 0.86% |
| Xtx Topco Ltd | 0.49% |
| Citadel | 0.39% |
| Two Sigma Securities, LLC | 0.31% |
| Rhumbline Advisers | 0.21% |
| BNP Paribas Financial Markets | 0.13% |
Source: Nexqual, July 25, 2026 at 07:45 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATHE | Alterity Therapeutics Limited | USD 4.54 | ▼ 3.4% |
| EDSA | Edesa Biotech, Inc. | USD 5.25 | ▼ 7.57% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.14 | ▼ 1.72% |
| WAFU | Wah Fu Education Group Limited | USD 1.54 | ▼ 6.79% |
| KZIA | Kazia Therapeutics Limited | USD 12.26 | ▼ 16.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:45 UTC. This page is informational and not investment advice.